ArticleCancer cell international2020
Breast cancer organoids from a patient with giant papillary carcinoma as a high-fidelity model.
Article in Cancer cell international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Chemotherapy improves survival for patients with lymph node-negative invasive papillary breast cancer with tumors ≥2 cm: a SEER population-based study.The oncologist · 2026Article
- Mucinous breast cancer organoids: an in vitro research model.Discover oncology · 2025Article
- Organoids as a model system for researching human neuroendocrine tumor of the breast.Cancer cell international · 2024Article
- Integrative Analysis Reveals STC2 as a Prognostic Biomarker of Laryngeal Squamous Cell Carcinoma.Applied biochemistry and biotechnology · 2024Article
- Organoids as preclinical models of human disease: progress and applications.Medical review (2021) · 2024Review
- Cancer organoids: A platform in basic and translational research.Genes & diseases · 2024Review
- Tumor Organoid as a Drug Screening Platform for Cancer Research.Current stem cell research & therapy · 2024Review
- Invasive papillary carcinoma of the breast.Frontiers in oncology · 2024Review
- Human liver organoids for disease modeling of fibrolamellar carcinoma.Stem cell reports · 2022Article
- Patient Derived Ex-Vivo Cancer Models in Drug Development, Personalized Medicine, and Radiotherapy.Cancers · 2022Review
- Tumor organoids: applications in cancer modeling and potentials in precision medicine.Journal of hematology & oncology · 2022Review
- Combining Organoid Models with Next-Generation Sequencing to Reveal Tumor Heterogeneity and Predict Therapeutic Response in Breast Cancer.Journal of oncology · 2022Article
- Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy.Cancer communications (London, England) · 2021Review
- Ultrastructural analysis of breast cancer patient-derived organoids.Cancer cell international · 2021Article
- Breast cancer organoids from malignant pleural effusion-derived tumor cells as an individualized medicine platform.In vitro cellular & developmental biology. Animal · 2021Article
- Microvascularized tumor organoids-on-chips: advancing preclinical drug screening with pathophysiological relevance.Nano convergence · 2021Review
- Optimizing individualized treatment strategy based on breast cancer organoid model.Clinical and translational medicine · 2021Article
- Article
- Patient-Derived Cancer Organoids as Predictors of Treatment Response.Frontiers in oncology · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPapillary carcinoma is an uncommon type of breast cancer. Additionally, patients with huge breast papillary carcinoma are extremely rare in clinical practice. To improve therapeutic effect on such patients, it is urgent to explore biologically and clinically relevant models of the disease to discover effective drugs.
methodsWe collected surgical tumor specimens from a 63-year-old Chinese woman who has been diagnosed breast papillary carcinoma. The tumor was more than 15 cm in diameter, and applied to establish patient-derived papillary carcinoma organoids that could continuously propagate for more than 6 months.
resultsThe papillary carcinoma organoids matched the histological characteristics of orginal tumor by H&E staining identification, and maintained the expression of the breast cancer biomarkers by IHC, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor (HER2) and antigen Ki-67 (Ki67). In addition, we performed a 3-D drug screening to examine the effects of endocrine drugs (Fulvestrant, Tamoxifen) and targeted therapy drugs (Palbociclib, Everolimus, BKM120) on breast papillary carcinoma in the mimic in vivo environment. The drug sensitivities of our breast papillary carcinoma organoids were investigated as follows, Fulvestrant (IC
conclusionsThese results showed that an effective organoid platform for 3-D in vitro culture of breast cancer organoids from patients with breast papillary carcinoma could be used to identify possible treatments, and might be commonly applied to explore clinicopathological characteristics of breast papillary carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.